These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25108232)

  • 1. AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer.
    Xie Y; Hicks MJ; Kaminsky SM; Moore MA; Crystal RG; Rafii A
    Gynecol Oncol; 2014 Nov; 135(2):325-32. PubMed ID: 25108232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors.
    Watanabe M; Boyer JL; Crystal RG
    Gene Ther; 2010 Aug; 17(8):1042-51. PubMed ID: 20596059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma.
    Hicks MJ; Funato K; Wang L; Aronowitz E; Dyke JP; Ballon DJ; Havlicek DF; Frenk EZ; De BP; Chiuchiolo MJ; Sondhi D; Hackett NR; Kaminsky SM; Tabar V; Crystal RG
    Cancer Gene Ther; 2015 Jan; 22(1):1-8. PubMed ID: 25501993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab.
    Mao Y; Kiss S; Boyer JL; Hackett NR; Qiu J; Carbone A; Mezey JG; Kaminsky SM; D'Amico DJ; Crystal RG
    Hum Gene Ther; 2011 Dec; 22(12):1525-35. PubMed ID: 21801028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice.
    Watanabe M; Boyer JL; Hackett NR; Qiu J; Crystal RG
    Hum Gene Ther; 2008 Mar; 19(3):300-10. PubMed ID: 18324912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer.
    Isayeva T; Ren C; Ponnazhagan S
    Clin Cancer Res; 2005 Feb; 11(3):1342-7. PubMed ID: 15709207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer.
    Shao M; Hollar S; Chambliss D; Schmitt J; Emerson R; Chelladurai B; Perkins S; Ivan M; Matei D
    Mol Cancer Ther; 2012 Jul; 11(7):1576-86. PubMed ID: 22700681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice.
    Yagi Y; Fushida S; Harada S; Tsukada T; Kinoshita J; Oyama K; Fujita H; Ninomiya I; Fujimura T; Kayahara M; Kinuya S; Yashiro M; Hirakawa K; Ohta T
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):745-53. PubMed ID: 20033809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer.
    Shah DK; Veith J; Bernacki RJ; Balthasar JP
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):951-8. PubMed ID: 21305289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer.
    Huynh H; Teo CC; Soo KC
    Mol Cancer Ther; 2007 Nov; 6(11):2959-66. PubMed ID: 18025280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice.
    Subramanian IV; Ghebre R; Ramakrishnan S
    Gene Ther; 2005 Jan; 12(1):30-8. PubMed ID: 15550927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model.
    van der Bilt AR; Terwisscha van Scheltinga AG; Timmer-Bosscha H; Schröder CP; Pot L; Kosterink JG; van der Zee AG; Lub-de Hooge MN; de Jong S; de Vries EG; Reyners AK
    Clin Cancer Res; 2012 Nov; 18(22):6306-14. PubMed ID: 23014526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.
    Mabuchi S; Terai Y; Morishige K; Tanabe-Kimura A; Sasaki H; Kanemura M; Tsunetoh S; Tanaka Y; Sakata M; Burger RA; Kimura T; Ohmichi M
    Clin Cancer Res; 2008 Dec; 14(23):7781-9. PubMed ID: 19047105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer.
    Kim TJ; Landen CN; Lin YG; Mangala LS; Lu C; Nick AM; Stone RL; Merritt WM; Armaiz-Pena G; Jennings NB; Coleman RL; Tice DA; Sood AK
    Cancer Biol Ther; 2009 Dec; 8(23):2263-72. PubMed ID: 19829059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft.
    Inoue S; Hartman A; Branch CD; Bucana CD; Bekele BN; Stephens LC; Chada S; Ramesh R
    Mol Ther; 2007 Feb; 15(2):287-94. PubMed ID: 17235306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/Flt-1 using adeno-associated virus serotype 1-derived vector.
    Takei Y; Mizukami H; Saga Y; Yoshimura I; Hasumi Y; Takayama T; Kohno T; Matsushita T; Okada T; Kume A; Suzuki M; Ozawa K
    Int J Cancer; 2007 Jan; 120(2):278-84. PubMed ID: 17066424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model.
    Yu L; Wang Y; Yao Y; Li W; Lai Q; Li J; Zhou Y; Kang T; Xie Y; Wu Y; Chen X; Yi C; Gou L; Yang J
    Int J Gynecol Cancer; 2014 Sep; 24(7):1158-64. PubMed ID: 24987913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.
    Lu C; Shahzad MM; Moreno-Smith M; Lin YG; Jennings NB; Allen JK; Landen CN; Mangala LS; Armaiz-Pena GN; Schmandt R; Nick AM; Stone RL; Jaffe RB; Coleman RL; Sood AK
    Cancer Biol Ther; 2010 Feb; 9(3):176-82. PubMed ID: 20009575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.
    Nagengast WB; de Korte MA; Oude Munnink TH; Timmer-Bosscha H; den Dunnen WF; Hollema H; de Jong JR; Jensen MR; Quadt C; Garcia-Echeverria C; van Dongen GA; Lub-de Hooge MN; Schröder CP; de Vries EG
    J Nucl Med; 2010 May; 51(5):761-7. PubMed ID: 20395337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppressive effect of bevacizumab on peritoneal dissemination from gastric cancer in a peritoneal metastasis model.
    Imaizumi T; Aoyagi K; Miyagi M; Shirouzu K
    Surg Today; 2010 Sep; 40(9):851-7. PubMed ID: 20740349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.